TSX:WELL - Post Discussion
Post by
davgro on Mar 22, 2023 12:41pm
Buy Rating Reiterated at Stifel GMP, Target Kept at C$13.50
WELL Health Technologies Buy Rating Reiterated at Stifel GMP Following Good Q4 Results; Price Target Kept at C$13.50 2023-03-22 11:56:22 AM ET (MT Newswires)
11:56 AM EDT, 03/22/2023 (MT Newswires) -- Stifel GMP on Wednesday reiterated its buy rating on the shares of WELL Health Technologies (WELL.TO) and its C$13.50 price target reported fourth-quarter results.
"WELL, a diversified OMNI channel healthcare provider, reported good Q4 results (end Dec.), demonstrating continued solid growth at higher scale," analyst Justin Keywood wrote. "Q4 sales of $157mm, was up 35% YoY, exceeded estimates and included ~20% organic growth. Solid growth is expected to continue and WELL issued new 2023 guidance with an expectation for $665mm-$685mm of revenue, up 17-20% YoY and above prior estimates. The company also spoke to a medium-term target for $1b in sales within three years with an expectation of 20% adj. EBITDA margin and implying almost double the EBITDA from 2022. We continue to favor WELL as a high growth play in healthcare, where there are few ways to gain exposure to billions of new Federal funding in Canada, along with a developing two-tiered healthcare system. WELL has the largest network of primary and specialty care clinics in the country, and we expect this position to strengthen ahead."
Be the first to comment on this post